Newsroom

Justifying After the Fact Is Not Justification

What the study should have asked is whether or not the price Gilead set for the therapy is appropriate for all patients–even asymptomatic patients–and whether or not such a large portion of potential societal value should accrue to one company.

Read more

[Health Affairs] The $500 Billion Medicare Slowdown: A Story About Part D

A great deal of analysis has been published on the causes of the health care spending slowdown system-wide — including in the pages of Health Affairs.

Read more

[PBS NewsHour] Small group of specialty drugs could make up half of total pharmacy spending by 2018

Some patients are paying sky-high prices for ‘specialty medications’ when cheaper options exist, a team of researchers has found.

Read more

[SF Business Times] Gilead’s $1,000-a-pill hepatitis C drug may make financial sense for prisons

Pricey new hepatitis C drugs, such as Gilead Sciences Inc.’s Sovaldi, may make financial sense to give to give to prisoners, one of the main groups infected with the liver-damaging virus, according to a team of Stanford University researchers.

Read more